PBLSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Parabilis Medicines, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$25.35+2.60 (+11.43%)

Close on Oct 19, 2026

Market cap: $732.82M
P/E (TTM): –
Dividend yield: –

Parabilis Medicines, Inc. income statement

Annual data is not available for this company.

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q2 2025 2025-06-30	Q1 2025 2025-03-31
Revenue	0.15	–	0	–
Research & Development	39	–	30	–
General & Administrative	12	–	6.39	–
Operating Expenses	51	–	37	–
Operating Income	-51	–	-37	–
Interest Expense	0.21	–	0.40	–
Interest & Investment Income	4.19	–	1.05	–
Other Non-Operating Income	-1.58	–	1.71	–
Net Income incl. Noncontrolling Interests	-52	–	-35	–
Net Income	-52	-45	-35	-38
Net Income to Common	-67	–	-45	–
EPS (Basic)(per share)	-2.32	–	-22.28	–
EPS (Diluted)(per share)	-2.32	–	-22.28	–
Shares Outstanding (Basic, Weighted)(shares)	29	–	2.02	–
Shares Outstanding (Diluted, Weighted)(shares)	29	–	2.02	–
EBITDA	-50	–	-36	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 17.91
Debt to equity: 0.01
Debt to assets: 0.5%
Cash to current liabilities: 1729.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.70
Dividend yield: –